Wishing you a year filled with health, happiness, peace, and prosperity. CHEERS! #HappyNewYear2025!
TissueCypher - Barrett's Esophagus
Medical and Diagnostic Laboratories
Pittsburgh, Pennsylvania 1,926 followers
The first precision medicine test for risk stratification of BE patients at risk for progressing to cancer
About us
For patients with Barret’s esophagus (BE), TissueCypher provides a 5-year individual risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). TissueCypher transforms disease management of patients with BE by identifying two important sets of patients: 1. Those at high risk for future progression to cancer or harboring prevalent HGD/EAC; and, 2. Those at low risk of progression who may be able to avoid unnecessary treatment or surveillance. TissueCypher clinical utility and validation has been demonstrated in nine peer-reviewed publications with leading medical centers in the US and Europe, utilizing the largest set of BE progressor patients ever assembled. Overall this body of data demonstrates that a TissueCypher high risk score independently predicts an almost 8-fold increased risk of progression to esophageal cancer (Mayo pooled analysis reference), and has been shows to be the strongest predictor of progression to esophageal cancer. The test utilizes existing tissue biopsies and is indicated for patients diagnosed with Barrett’s esophagus where their tissue pathology has come back as non-dysplastic, indefinite for dysplasia, or low-grade dysplasia. TissueCypher utilizes nine protein biomarkers and 15 digital features of epithelial and stromal cell abnormalities involved in carcinogenesis and nuclear morphology. Tissue slides are stained, imaged, and analyzed using a locked AI-driven algorithm that automatically and objectively provides patients and physicians with an easy to interpret and clinically actionable low, intermediate, and high-risk classification and a projected 5-year risk of progression.
- Website
-
https://castlebiosciences.com/TissueCypher
External link for TissueCypher - Barrett's Esophagus
- Industry
- Medical and Diagnostic Laboratories
- Company size
- 501-1,000 employees
- Headquarters
- Pittsburgh, Pennsylvania
Updates
-
Here's this week's #CasesWithCastle episode featuring Dr. Charles Loewe treating an anxious #BarrettsEsophagus patient who had strong reasons for worry -- the patient's brother had already been diagnosed with esophageal cancer. Check the comments for the link to the case details ↓↓ “TissueCypher helped us to reassure [the patient] that he was making the right decision, lowered his anxiety, and gave him a high confidence level."
-
TissueCypher - Barrett's Esophagus reposted this
Gastroenterologist & Biotech Medical Director leading AI & Precision Medicine Initiatives
I am honored to share this interview with Dr. Cadman Leggett, a physician at Mayo Clinic, featured in USA Today. It is deeply humbling to learn that Dr. Leggett's unwavering advocacy for advancing the care of patients with Barrett’s esophagus (BE) stems from a personal loss. The fight against BE and esophageal cancer is fraught with challenges, including the lack of universal coverage for screening, inadequate coverage for prognostic tests, and hesitancy to seek early medical care for patients at risk. In today’s challenging insurance landscape, we must persist in our efforts to expand access to advancements in Precision Medicine—such as TissueCypher - Barrett's Esophagus - so that more patients can benefit from personalized, cutting-edge care. https://lnkd.in/gCVR3KQP
-
-
Read about TissueCypher — A Game-Changing Test in the Fight Against Esophageal Cancer — on page 10...
🌟 Our Digestive Health & Diseases Campaign Has Launched! 🌟 This campaign explores the latest advancements in digestive care, highlights expert insights, and provides actionable information to help individuals better understand and manage their gut health. From prevention and early diagnosis to cutting-edge treatment options, we’re shining a light on the importance of digestive health for everyone. Check out the full campaign here: https://lnkd.in/eFSJ_XtV Thank you to our partners! VIVUS LLC Castle Biosciences, Inc. Iterative Health Takeda Guardant Health Exact Sciences Medtronic Olympus Corporation Salix Pharmaceuticals Herbalife American Liver Foundation American Gastroenterological Association (AGA) Colorectal Cancer Alliance GI Alliance Dr Megan Rossi Amway
-
Castle Biosciences' TissueCypher® test can offer patients with Barrett's esophagus a clearer picture of their risk of developing esophageal cancer, which is the 8th most common form of cancer worldwide and the 6th leading cause of cancer death (due in part to late diagnoses). Learn more about how TissueCypher can help (via USA TODAY and Mediaplanet USA): https://lnkd.in/gMBycc73
-
“[The patient] said to me: ‘Are you going to do anything with my Barrett’s at this time?'…I said, ‘TissueCypher will give us that answer to lower your anxiety.’ ” In this episode of #CasesWithCastle, Dr. Charles Loewe with Florida Digestive Health Specialists leverages #TissueCypher to help a highly anxious patient with a long history of GERD and recent trouble swallowing. Check the comments for the link to the case details ↓↓
-
Always a good time in NYC! The #TissueCypher team is happy to be in the Big Apple at the 48th Annual New York Course. This week, LJ DelPonte, Kim & Noelle Chin-Sang have had the opportunity to share with physicians how risk-stratification for #BarrettsEsophagus patients can help lower the incidence of #EsophagealCancer through personalized, precision medicine.
-
-
TissueCypher - Barrett's Esophagus reposted this
Director of Endoscopy, System Director of Interventional Endoscopy, Director of Quality & Endoscopic Research at Geisinger
Such a collaborative evening of education and learning with our Northeast Geisinger GI teams from GEISINGER WYOMING VALLEY MED CENTER and GEISINGER COMMUNITY MEDICAL CENTER, building a systemwide comprehensive esophageal diseases management program, with cutting edge diagnostic and therapeutic interventions for our patients with #Barretts esophagus! We discussed the role of TissueCypher - Barrett's Esophagus and the published data behind the test, many of which came from Geisinger Medical Center! Kudos to Jennifer K. from Castle Biosciences, Inc. for hosting and supporting our program!
-
-
Dr. Charles Loewe, a founding member of Florida Digestive Health Specialists in Sarasota, Fla., is passionate about leveraging well-validated technology to help patients he diagnoses with #BarrettsEsophagus (BE). In the coming weeks, we will be sharing a few of his cases where #TissueCypher helped to improve patient care. But first, we wanted to share his overall thoughts on the test. “Having the TissueCypher score has greatly improved our sense of well-being,” he says. You can browse Dr. Loewe's cases here: https://hubs.la/Q02_kbvM0